First AD

Second AD

Standard of care for frontline treatment of non-V600E-specific pLGG tumors

Briefly describe the standard of care options for frontline treatment of pLGG tumors (

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Video Series

Novel Breakthroughs in Management of Pediatric Low-Grade Glioma (pLGG)

The experts in pediatric low-grade gliomas (pLGG) delineate the standard of care for frontline treatment of tumors not harboring the BRAF V600E mutation, outlining current best practices and therapeutic approaches.

Overview of pLGG presentation and categorization

Molecular Characterization of pLGG

Less Common Molecular Alterations in pLGG and Testing Recommendations

Ongoing clinical trials for frontline treatment of non-V600E-specific pLGG tumors

Current Treatment of Patients with NF1 pLGG

Standard of Care Pptions Specific for Frontline Treatment of BRAF V600E-Mutated pLGG

Treatment Considerations for Progressive pLGG

Radiation and Targeted Therapies for Progressive pLGG

The Role of Tovorafenib in Treatment of Progressive pLGG

Clinical Trials to Increase Treatment Options in the Progressive Setting

Clinical scenario 1 - BRAFKIAA-1549 fusion

Alternatives and Considerations for Clinical Scenario 1

Clinical Scenario 2 - BRAFV600E

Potential Adverse Events With Targeted Therapies

Clinical Insights: Looking Forward for pLGG